The effects of age on antibody response towards COVID-19 vaccination: A Systematic Review

Hendra Ikhwan Gautama, Gatot Soegiarto, Laksmi Wulandari

Abstract


Background: Mortality rate of COVID-19 infection isexceptionally high in the older population. Various vaccines are being rapidly developed as an attempt to halt the pandemic. Although vaccination has been effective in reducing mortality and hospitalization rate in recent months, lower vaccine effectiveness has been reported among older adults.

Aim: This review aims to evaluate and summarize current evidence on the effect of age on antibody response towards COVID-19 vaccines. 

Methods: Literature search was conducted on PubMed, Scopus, ScienceDirect and ProQuest for studies published up to 9th October 2022. The selected studies were assessed The Joanna Briggs critical appraisal tools. Qualitative analysis was then performed for the final studies.

Result: A final of 9 studies were included in this review. A majority of the studies evaluated the responses of BNT162b2 or mRNA-1273 vaccine, while 1 study investigated the response towards ChAdOx1 vaccine. Outcomes were measured in term of IgG antibody levels or serum neutralization. Most studies demonstrated significantly lower antibody response and neutralization in older adults compared to younger vaccinees after administration of first and second vaccine dose. However, two studies reported no significant difference in vaccine responses across age groups after third dose administration.

Conclusion: This systematic review highlights lowerimmunogenicity towards COVID-19 vaccines in older population. Further research into strategies to improve vaccine responses in the elderly is required to provide sufficient protection for this vulnerable group.

 

Keywords: COVID-19 vaccine, antibody, neutralization, age, elderly


Full Text:

PDF

References


Alexandridi, M., Mazej, J., Palermo, E., & Hiscott, J. (2022). The Coronavirus pandemic – 2022: Viruses, variants & vaccines. Cytokine & Growth Factor Reviews, 63, 1–9. https://doi.org/10.1016/j.cytogfr.2022.02.002

Arregocés-Castillo, L., Fernández-Niño, J., Rojas-Botero, M., Palacios-Clavijo, A., Galvis-Pedraza, M., Rincón-Medrano, L., Pinto-Álvarez, M., Ruiz-Gómez, F., & Trejo-Valdivia, B. (2022). Effectiveness of COVID-19 vaccines in older adults in Colombia: a retrospective, population-based study of the ESPERANZA cohort. The Lancet Healthy Longevity, 3(4), e242–e252. https://doi.org/10.1016/S2666-7568(22)00035-6

Bartleson, J. M., Radenkovic, D., Covarrubias, A. J., Furman, D., Winer, D. A., & Verdin, E. (2021). SARS-CoV-2, COVID-19 and the aging immune system. Nature. https://doi.org/https://doi.org/10.1038/s43587-021-00114-7

Bonanad, C., García-Blas, S., Tarazona-Santabalbina, F., Sanchis, J., Bertomeu-González, V., Fácila, L., Ariza, A., Núñez, J., & Cordero, A. (2020). The Effect of Age on Mortality in Patients With COVID-19: A Meta-Analysis With 611,583 Subjects. Journal of the American Medical Directors Association, 21(7), 915–918. https://doi.org/10.1016/j.jamda.2020.05.045

Brockman, M. A., Mwimanzi, F., Lapointe, H. R., Sang, Y., Agafitei, O., Cheung, P. K., Ennis, S., Ng, K., Basra, S., Lim, L. Y., Yaseen, F., Young, L., Umviligihozo, G., Omondi, F. H., Kalikawe, R., Burns, L., Brumme, C. J., Leung, V., Montaner, J. S. G., … Brumme, Z. L. (2022). Reduced Magnitude and Durability of Humoral Immune Responses to COVID-19 mRNA Vaccines Among Older Adults. The Journal of Infectious Diseases, 225(7), 1129–1140. https://doi.org/10.1093/infdis/jiab592

Collier, D. A., Ferreira, I. A. T. M., Kotagiri, P., Datir, R. P., Lim, E. Y., Touizer, E., Meng, B., Abdullahi, A., Baker, S., Dougan, G., Hess, C., Kingston, N., Lehner, P. J., Lyons, P. A., Matheson, N. J., Owehand, W. H., Saunders, C., Summers, C., Thaventhiran, J. E. D., … Gupta, R. K. (2021). Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2. Nature, 596(7872), 417–422. https://doi.org/10.1038/s41586-021-03739-1

Connors, J., Bell, M. R., Marcy, J., Kutzler, M., & Haddad, E. K. (2021). The impact of immuno-aging on SARS-CoV-2 vaccine development. GeroScience, 43(1), 31–51. https://doi.org/10.1007/s11357-021-00323-3

Crooke, S. N., Ovsyannikova, I. G., Poland, G. A., & Kennedy, R. B. (2019). Immunosenescence and human vaccine immune responses. Immunity & Ageing, 16(1), 25. https://doi.org/10.1186/s12979-019-0164-9

Demaret, J., Corroyer-Simovic, B., Alidjinou, E. K., Goffard, A., Trauet, J., Miczek, S., Vuotto, F., Dendooven, A., Huvent-Grelle, D., Podvin, J., Dreuil, D., Faure, K., Deplanque, D., Bocket, L., Duhamel, A., Labreuche, J., Sobaszek, A., Hisbergues, M., Puisieux, F., … Lefèvre, G. (2021). Impaired Functional T-Cell Response to SARS-CoV-2 After Two Doses of BNT162b2 mRNA Vaccine in Older People. Frontiers in Immunology, 12. https://doi.org/10.3389/fimmu.2021.778679

Eliakim-Raz, N., Leibovici-Weisman, Y., Stemmer, A., Ness, A., Awwad, M., Ghantous, N., & Stemmer, S. M. (2021). Antibody Titers Before and After a Third Dose of the SARS-CoV-2 BNT162b2 Vaccine in Adults Aged ≥60 Years. JAMA, 326(21), 2203. https://doi.org/10.1001/jama.2021.19885

Eyal, N., Gheaus, A., Gosseries, A., Magalhaes, M., Ngosso, T., Steuwer, B., Tangcharoensathien, V., Trifan, I., & Williams, A. (2022). Coronavirus Disease 2019 (COVID-19) Vaccine Prioritization in Low- and Middle-Income Countries May Justifiably Depart From High-Income Countries’ Age Priorities. Clinical Infectious Diseases, 75(Supplement_1), S93–S97. https://doi.org/10.1093/cid/ciac398

Frasca, D., Diaz, A., Romero, M., & Blomberg, B. B. (2016). The generation of memory B cells is maintained, but the antibody response is not, in the elderly after repeated influenza immunizations. Vaccine, 34(25), 2834–2840. https://doi.org/10.1016/j.vaccine.2016.04.023

Fulop, T., Larbi, A., Pawelec, G., Cohen, A. A., Provost, G., Khalil, A., Lacombe, G., Rodrigues, S., Desroches, M., Hirokawa, K., Franceschi, C., & Witkowski, J. M. (2022). Immunosenescence and Altered Vaccine Efficiency in Older Subjects: A Myth Difficult to Change. Vaccines, 10(4), 607. https://doi.org/10.3390/vaccines10040607

Gold, J. A. W., Rossen, L. M., Ahmad, F. B., Sutton, P., Li, Z., Salvatore, P. P., Coyle, J. P., DeCuir, J., Baack, B. N., Durant, T. M., Dominguez, K. L., Henley, S. J., Annor, F. B., Fuld, J., Dee, D. L., Bhattarai, A., & Jackson, B. R. (2020). Race, Ethnicity, and Age Trends in Persons Who Died from COVID-19 — United States, May–August 2020. MMWR. Morbidity and Mortality Weekly Report, 69(42), 1517–1521. https://doi.org/10.15585/mmwr.mm6942e1

Gustafson, C. E., Kim, C., Weyand, C. M., & Goronzy, J. J. (2020). Influence of immune aging on vaccine responses. Journal of Allergy and Clinical Immunology, 145(5), 1309–1321. https://doi.org/10.1016/j.jaci.2020.03.017

Khoury, D. S., Cromer, D., Reynaldi, A., Schlub, T. E., Wheatley, A. K., Juno, J. A., Subbarao, K., Kent, S. J., Triccas, J. A., & Davenport, M. P. (2021). Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nature Medicine, 27(7), 1205–1211. https://doi.org/10.1038/s41591-021-01377-8

Luczkowiak, J., Rivas, G., Labiod, N., Lasala, F., Rolo, M., Lora‐Tamayo, J., Mancheno‐Losa, M., Rial‐Crestelo, D., Pérez‐Rivilla, A., Folgueira, M. D., & Delgado, R. (2023). Cross neutralization of SARS‐CoV‐2 omicron subvariants after repeated doses of COVID‐19 mRNA vaccines. Journal of Medical Virology, 95(1). https://doi.org/10.1002/jmv.28268

Lv, G., Yuan, J., Xiong, X., & Li, M. (2021). Mortality Rate and Characteristics of Deaths Following COVID-19 Vaccination. Frontiers in Medicine, 8. https://doi.org/10.3389/fmed.2021.670370

Müller, L., Andrée, M., Moskorz, W., Drexler, I., Walotka, L., Grothmann, R., Ptok, J., Hillebrandt, J., Ritchie, A., Rabl, D., Ostermann, P. N., Robitzsch, R., Hauka, S., Walker, A., Menne, C., Grutza, R., Timm, J., Adams, O., & Schaal, H. (2021). Age-dependent Immune Response to the Biontech/Pfizer BNT162b2 Coronavirus Disease 2019 Vaccination. Clinical Infectious Diseases, 73(11), 2065–2072. https://doi.org/10.1093/cid/ciab381

Mwimanzi, F., Lapointe, H. R., Cheung, P. K., Sang, Y., Yaseen, F., Umviligihozo, G., Kalikawe, R., Datwani, S., Omondi, F. H., Burns, L., Young, L., Leung, V., Agafitei, O., Ennis, S., Dong, W., Basra, S., Lim, L. Y., Ng, K., Pantophlet, R., … Brockman, M. A. (2022). Older Adults Mount Less Durable Humoral Responses to Two Doses of COVID-19 mRNA Vaccine but Strong Initial Responses to a Third Dose. The Journal of Infectious Diseases, 226(6), 983–994. https://doi.org/10.1093/infdis/jiac199

Pawelec, G., & Weng, N. (2020). Can an effective SARS-CoV-2 vaccine be developed for the older population? Immunity & Ageing, 17(1), 8. https://doi.org/10.1186/s12979-020-00180-2

Pereira, B., Xu, X.-N., & Akbar, A. N. (2020). Targeting Inflammation and Immunosenescence to Improve Vaccine Responses in the Elderly. Frontiers in Immunology, 11. https://doi.org/10.3389/fimmu.2020.583019

Ramasamy, M. N., Minassian, A. M., Ewer, K. J., Flaxman, A. L., Folegatti, P. M., Owens, D. R., Voysey, M., Aley, P. K., Angus, B., Babbage, G., Belij-Rammerstorfer, S., Berry, L., Bibi, S., Bittaye, M., Cathie, K., Chappell, H., Charlton, S., Cicconi, P., Clutterbuck, E. A., … Zizi, D. (2020). Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. The Lancet, 396(10267), 1979–1993. https://doi.org/10.1016/S0140-6736(20)32466-1

Richards, N. E., Keshavarz, B., Workman, L. J., Nelson, M. R., Platts-Mills, T. A. E., & Wilson, J. M. (2021). Comparison of SARS-CoV-2 Antibody Response by Age Among Recipients of the BNT162b2 vs the mRNA-1273 Vaccine. JAMA Network Open, 4(9), e2124331. https://doi.org/10.1001/jamanetworkopen.2021.24331

Schenkelberg, T. (2021). Vaccine-induced protection in aging adults and pandemic response. Biochemical and Biophysical Research Communications, 538, 218–220. https://doi.org/10.1016/j.bbrc.2020.10.090

Surendra, H., Elyazar, I. R., Djaafara, B. A., Ekawati, L. L., Saraswati, K., Adrian, V., Widyastuti, Oktavia, D., Salama, N., Lina, R. N., Andrianto, A., Lestari, K. D., Burhan, E., Shankar, A. H., Thwaites, G., Baird, J. K., & Hamers, R. L. (2021). Clinical characteristics and mortality associated with COVID-19 in Jakarta, Indonesia: A hospital-based retrospective cohort study. The Lancet Regional Health - Western Pacific, 9, 100108. https://doi.org/10.1016/j.lanwpc.2021.100108

Vassilaki, N., Gargalionis, A. N., Bletsa, A., Papamichalopoulos, N., Kontou, E., Gkika, M., Patas, K., Theodoridis, D., Manolis, I., Ioannidis, A., Milona, R. S., Tsirogianni, A., Angelakis, E., & Chatzipanagiotou, S. (2021). Impact of Age and Sex on Antibody Response Following the Second Dose of COVID-19 BNT162b2 mRNA Vaccine in Greek Healthcare Workers. Microorganisms, 9(8), 1725. https://doi.org/10.3390/microorganisms9081725

World Health Organization. (2022). COVID-19 Weekly Epidemiological Update.




DOI: http://dx.doi.org/10.30829/jumantik.v8i1.13631

Refbacks

  • There are currently no refbacks.


Copyright (c) 2023 Hendra Ikhwan Gautama

Creative Commons License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.